St. Petersburg
2019 November 5-7th
Inhibits virus reproduction
Reduces the duration of illness by three days
Reduces the risk of pneumonia by 99%
Reduces the risk of infection 7 times

4. the beginning of the treatment within the first 48 hours. compared with patients without antiviral therapy.
NPO Petrovax Pharm is the leading Russian full-cycle biopharmaceuticals company focusing on original pharmaceutical products and vaccines.

20 years of experience on the pharma market

- Original product and vaccine portfolio
- R&D platform
- GMP- and ISO-compliant manufacturing process
- Pharmaceutical exports to the EAEU, EU, and Iran
- Joint international projects with pharma industry leaders

www.petrovax.ru
Welcome to Virology Days International Scientific Conference in Saint Petersburg that unites science, education, technology and industry. This event has been co-organised by Smorodintsev Research Institute of Influenza, Center for Strategic Planning and Management of Medical and Biological Health Risks and Peter the Great St. Petersburg Polytechnic University. Virology Days aim to emphasize the importance of research in the field of virology globally and to unite virologists from all over Russia with their foreign colleagues.

The programme addresses the scientific basis for improved vaccines, development of a wider range of antivirals and improving preparedness to biological hazards. The speakers include many of those who contributed significantly to our better understanding of viral pathogenesis as well as young scientists.

We thank all who have contributed to the organization of Virology Days International Scientific Conference and are greatful to the generous support of our sponsors. We believe you will enjoy Virology Days International Scientific Conference and have stimulating experience.
Despite significant progress in the development of vaccines and antiviral drugs for the treatment of patients, influenza infection maintains a leading position in both the Russian and global infectious disease epidemiological structures. Influenza has an important medical and social significance; every year, seasonal influenza epidemics generate significant economic impacts. In addition, influenza is an infection with high pandemic potential. Pandemics occur several times a century and, to date, it is still impossible to predict the time and place of a new pandemic strain’s occurrence. Given the suddenness and unpredictability with which new influenza pandemic pathogens emerge, laboratory surveillance of influenza (unlike other infections) needs to be constantly updated and improved due to high pathogen variability. In this regard, ongoing strengthening and expansion of continuous etiological monitoring of influenza viruses and other acute respiratory viral infections, through the development of a multiplex surveillance system (routine, sentinel, hospital), remain priority tasks in the country.

To reduce influenza impacts, the WHO recommends annual vaccination of people at risk for developing severe acute respiratory infections (SARI) or fatal influenza complications. In recent years, more and more attention has been paid in developed countries, not only to vaccination coverage, but also to vaccination strategies, including evaluation of their effectiveness. The development and improvement of domestic vaccines, antiviral drugs, and diagnostic systems are of particular importance given Russia’s geographical situation, namely: an extended border with China, as well as mass tourism to Southeast Asia. Currently, Asia is clearly the center of diversity for all circulating influenza viruses that can infect humans. Over the past 20 years, potentially pandemic influenza A strains of subtypes A(H5N1), A(H7N9), A(H9N2), A(H10N8), A(H5N6), and others have come from Asia.

The Round Table aims to discuss key aspects related to the optimization of vaccine-based influenza prevention, such as: vaccine strain selection; formation of a National Commission for vaccine strains; introduction of quadrivalent vaccines; modern approaches to vaccine-based prevention for people over 60; compliance of domestic vaccines with international standards; effectiveness of vaccination against influenza and possible ways to increase it; as well as the creation of next-generation influenza vaccines.

Resolutions of the Round Table will be sent to the Russian Ministry of Health.
Номидес®
ЛОВУШКА ДЛЯ ВИРУСА ГРИППА

- Этиотропное противовирусное средство, снижающее осложнения гриппа на 55%

- Лечение и профилактика гриппа у взрослых и детей²

- Дозировки от года и старше²

Информация для специалистов здравоохранения. Перед применением ознакомьтесь с полной инструкцией по применению лекарственного препарата Номидес.

Список литературы:
2. Инструкция по применению

АО «ФАРМАСИНЕС» 664007, г. Иркутск, ул. Красногвардейская, д.23, оф.3 тел. (3952) 538503, www.nomides.ru
Second Russian-Chinese symposium on infectious diseases
November 6th

Opening ceremony

09-30 – 10-00  Representative from the MoH, representative from Centre of Strategic planning (MoH), representative from the Polytechnic University, representative from Smorodintsev Research Institute of influenza, representative from Chinese delegation (5 min each)

Influenza session
(Large conference Hall)

Surveillance and evolution of the virus

Session Chairs:  Alexander Shestopalov, Jinhua Liu

10-00 – 10-30  Plenary Talk:  Anna Sominina
Age structure and other risk factors for SARI determined in Global Influenza Hospital Surveillance Network

10-30 – 10-50  Artem Fadeev  A decade of pandemic influenza A(H1N1)pdm09 circulation in Russia: epidemiology, virology and possible outcomes

10-50 – 11-10  Liu Jinhua  Evolution and risk assessment of swine influenza virus in China

11-10 – 11-30  COFFEE BREAK (Cafe “Winter Garden”)

11-30 – 11-50  Zhu Wenfei  Human infection with zoonotic influenza

11-50 – 12-10  Alexander Shestopalov  Avian influenza in Russia

12-10 – 12-30  Jiang Taijiao  Bioinformatic approaches to influenza viruses

12-30 – 12-50  Vasilii Leonenko  Mathematic modelling in influenza epidemics

13-00 – 14-00  LUNCH (Cafe on the 1st floor)

Diagnostics, treatment and prophylaxis of influenza

Session Chairs:  German Shipulin, Jun Liu

14-00 – 14-30  Plenary Talk:  German Shipulin MDx – a key technology in diagnostics of infectious diseases

14-30 – 14-50  Liu Jun  The seroepidemiology of avian influenza A viruses in occupationally-exposed population of China

14-50 – 15-10  Andrey Vasin  RNA-based vector vaccines for influenza and other ARI

15-10 – 15-30  Aleksei Matveichev, Vladimir Talayev  Polyoxidonium adjuvant in low-dosed vaccines

15-30 – 16-00  COFFEE BREAK (Cafe “Winter Garden”)
November 6th

MAIN SYMPOSIUM
(Large conference Hall)

Session Chairs: German Shipulin, Liu Jun
(session continues)

16-00 – 16-20 Yuri Vasiliev
Vaccines for the control of influenza as viewed by different stakeholders

16-20 – 16-40 Igor Krasilnikov, Victor Truhin
Development of seasonal influenza vaccines in Russia

16-40 – 17-00 Anna Shtro
Recent advances in the development of antiviral agents

17-00 – 17-20 DISCUSSION:
Arbidol in Russia and China

SATELLITE SYMPOSIUM
(Small conference Hall)

The role of antivirals in the control of influenza and post-influenza complications

Session Chairs: Xuezhong Yu, Artem Poromov

16-00 – 16-20 Irina Leneva
Arbidol History - From Bench to Bedside

16-20 – 16-40 Zifeng Yang
The progress of clinical management of human avian influenza in southern China

16-40 – 17-00 Vasily Vlassov
Arbidol in seasonal and pandemic influenza: a review of clinical trials and 30-years experience in Russia

17-00 – 17-20 Yeming Wang
STAR trial: Oseltamivir and Arbidol combination antiviral therapy versus oseltamivir monotherapy for the treatment of severe influenza: a multicentre, double-blind, randomised phase 3 clinical trial

17-20 – 17-40 DISCUSSION:
Arbidol in Russia and China

17-40 – 20-00 WELCOME RECEPTION (Cafe “Winter Garden”)
### November 7th

#### TB session

**Session Chairs:** Viacheslav Zhuravlev, Haican Liu

<table>
<thead>
<tr>
<th>Time</th>
<th>Speaker(s)</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>09-30 – 10-00</td>
<td>Petr Yablonskiy, Viacheslav Zhuravlev</td>
<td>Plenary Talk: Tuberculosis in the third millennium. Reality and perspectives</td>
</tr>
<tr>
<td>10-00 – 10-20</td>
<td>Chen Wei</td>
<td>Introduction of TB Surveillance System and TB Epidemic in China</td>
</tr>
<tr>
<td>10:20 – 10-40</td>
<td>Zhang Hui</td>
<td>Strategy and Progress on Tuberculosis Control in China</td>
</tr>
<tr>
<td>10-40 – 11-00</td>
<td>Mikhail Sinitsyn</td>
<td>Tuberculosis and HIV/TB co-infection in Moscow</td>
</tr>
<tr>
<td>11-00 – 11-20</td>
<td>COFFEE BREAK (Cafe &quot;Winter Garden&quot;)</td>
<td></td>
</tr>
<tr>
<td>11-20 – 11-40</td>
<td>Zhao Yanlin</td>
<td>Big Data analysis of TB epidemic and transmission in China</td>
</tr>
<tr>
<td>11-40 – 12:00</td>
<td>Marina Stukova</td>
<td>Mucosal influenza vectored tuberculosis vaccines</td>
</tr>
<tr>
<td>12:00 – 12-20</td>
<td>Haican Liu</td>
<td>Current Status of Tuberculosis Vaccine Research in China</td>
</tr>
<tr>
<td>12-20 – 12-40</td>
<td>Valentin Makarov</td>
<td>Novel approaches based on genome editing technology for creation of the new anti-tuberculosis vaccines</td>
</tr>
<tr>
<td>12-50 – 14-00</td>
<td></td>
<td>LUNCH (Cafe on the 1st floor)</td>
</tr>
</tbody>
</table>

#### HIV session

**Session Chairs:** Xiaoping Dong, Andrei Kozlov

<table>
<thead>
<tr>
<th>Time</th>
<th>Speaker(s)</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>14-00 – 14-30</td>
<td>Dong Xiaoping</td>
<td>Plenary Talk: Belt &amp; Road, Public Health Development &amp; Collaboration</td>
</tr>
<tr>
<td>14-30 – 14:50</td>
<td>Andrei Kozlov</td>
<td>The overview of HIV research in Russia: from first cases of HIV infection to HIV vaccine trials</td>
</tr>
<tr>
<td>14-50 – 15:10</td>
<td>Dina Glazkova</td>
<td>Intracellular immunization as one of the approaches to HIV infection treatment</td>
</tr>
<tr>
<td>15-10 – 15:30</td>
<td>Eduard Karamov</td>
<td>HIV/TB co-infection in Russia</td>
</tr>
<tr>
<td>15-30 – 15:50</td>
<td>Wu Zunyou</td>
<td>Towards ending HIV epidemic among people who inject drugs in China</td>
</tr>
<tr>
<td>15-50 – 16:10</td>
<td>COFFEE BREAK (Cafe «Winter Garden»)</td>
<td></td>
</tr>
<tr>
<td>16-10 – 16:30</td>
<td>Zhang Linqi</td>
<td>Envelope changes during HIV transmission and adaptation: implications for vaccine development</td>
</tr>
<tr>
<td>16-30 – 16-50</td>
<td>Oksana Stanevich</td>
<td>Features of CDR3-junctions in broadly neutralizing antibodies in HIVinfected patients</td>
</tr>
<tr>
<td>16-50 – 17:10</td>
<td>Han Menglie</td>
<td>The Progress &amp; Challenge to Achieve Three 90% in China</td>
</tr>
<tr>
<td>17:10 – 17:30</td>
<td>Anastasiia Kholodnaya</td>
<td>Illicit opioids, bacterial translocation and systemic inflammation in HIVinfected patients</td>
</tr>
</tbody>
</table>

**CLOSING REMARKS**

Second Russian-Chinese symposium on infectious diseases
Wei Chen
Organization: NCTB, China CDC
Current position: Vice-director of the Division

Education experience:
- 1988.09–1993.07 Tongji Medical University MD
- 1998.09–2001.07 Tongji College of Medicine, Huazhong University of Science and Technology, MS in Epidemiology
- 2001.09–2004.07 China CDC, PhD in Epidemiology

Professional experience:
- 2004.07 – Present: Researcher, Division of Surveillance, National Center for Tuberculosis Control and Prevention, China CDC, working on construction of the TB information management system, assessment of the surveillance data quality control, Field epidemiology of Tuberculosis, research program on TB/HIV coinfection control, immigrant TB control, surveillance and prediction et.

Publications:

Research interests include
Surveillance and evaluation of TB, TB/HIV coinfection control.
Xiaoping Dong
Current position: Center for Global Public Health, China CDC
Current position: Director

MD & PhD, Professor of Virology. He is Director of Center for Global Public Health, China CDC; Deputy Director of State Key Lab for Infectious Disease Prevention and Control; Director of the Department of Prion Disease, IVDC. He got Bachelor of medicine from Xi'an Medical University in 1982, Master of Medicine, from Xi'an Medical University in 1988, and Doctor of Medicine from Erlangen-Nuernburg University, Germany in 1994. During 1995-1998, he worked as PostDoc and research scientist in Institute of Virology, Cologne University, Germany.

In 2003, he was honored as the outstanding oversee scholar issued by national ministry of personal and other five ministries. In 2006, he was selected as the national person with ability for new century. He is the syndic of Chinese Society of Microbiology and the Head of the Group of Medical Virology; the syndic of Chinese Society of Preventive Medicine and the members of Organization Committee and Scientific Committee. He is the scientific member of more ten special committees of national Ministries of Health, Agriculture, AQSIQ, SFDA and Chinese Society of Science. He is also the member of science board of more than ten international and Chinese scientific journals. Since 2000, he worked as PI of more than 30 research projects, including national 973, 863, Science and Technology Task Force, National Natural Science Foundation, Institution Technique R&D Grant and China Mega-Project for Infectious Disease. He worked as PI and co-PI of international collaborating projects, including NIH-CIPRA and EU Project.

Publications:

2. Shi Q, Sun H, Chen C, Zhang BY, Zhou W, Gao C, Dong XP. Treatment of redox process induces diverse effects on the recombinant human wild-type PrP and the mutated PrP with inserted or deleted octarepeats. Int J Mol Med

Research interests include:

His major research fields cover prion, human papillomavirus, emerging viral infectious diseases and R&D of vaccine. Up to the end of March 2018, he has published more than 300 scientific papers, including 176 SCI-cited English papers (157 papers as the corresponding author), including Lancet, Autophagy, EMBO J, Clin Infect Dis, Mol Cell Proteomics, Mol Neurobiol, JNNP, etc.
Mengjie Han
Organization: National Center for AIDS & STD Control and Prevention, China CDC
Current position: Director of the Center

Education:
- August 1999 – September 2001, Master of Public Policy and Management, University of Southern California, USA.
- August 1982 – July 1987, Bachelor of Medical Science, Bethune Medical University, China.

Grants and Awards:
Awarded the 2010 and 2012 Chinese Medical Science and Technology Award for Health Management. Awarded the 2018 Huaxia Medical Science and Technology Award for Second Prize.

Professional Experience:
Over the past 15 years, the work focused on delivering a comprehensive response to HIV/AIDS, holding a variety of responsibilities in the fields of policy and program development, project management and monitoring and evaluation, and multi-sector engagement and Community-Based Organization participation. Relevant work experiences include: Assistant Director of the AIDS State Council Office in China, Executive Director of the China Comprehensive AIDS Response program, Director of the China-UK CHARTS project, Focal Point of the Technological Network on HIV/AIDs in 8 countries, Leading Researcher on China-Africa Health Cooperation on HIV/AIDS, Worked as Scientist in the HIV/AIDS department at WHO on guideline development for prevention and treatment of HIV/AIDS among key populations.

Publications:

Research interests include:
HIV/AIDS Prevention and Treatment, Policy and Program Development, Monitoring & Evaluation, Multi-Sector Engagement and NGO Involvement.
Taijiao Jiang
Organization: Chinese Academy of Medical Sciences & Peking Union Medical College
Current position: Professor

Dr. Taijiao Jiang is the distinguished Professor of computational and systems biology, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences & Peking Union Medical College. Principal investigator of Suzhou Institute of System Medicine, He is one of the Standing Council Members of Biophysical Society of China and the Director of the Bioinformatics Branch and has been awarded NSFC Outstanding Youth Award, Hundred Talents Project Award and Distinguished Professor of Peking Union Medical College, etc. Jiang Lab is mainly focused on computational biology and systems medicine. The lab is now undertaking or has completed over 10 national and provincial level scientific research projects including those of national “973” project and the Natural Science Foundation of China.

- 1990–1994 B.S. Biology  Hunan Normal University, Changsha, China
- 1994–1999 Ph.D. Molecular Biology and Biochemistry  Shanghai Institute of Biochemistry, Chinese Academy of Sciences, Shanghai, China.
- 2001–2002 Master of computer science  Department of Computer Science, Yale.

Publications:

Research interests include:
- Development of novel computational methods for protein structure prediction, genomic co-evolution analysis, bio-medical data mining and complex network modeling.
- Development of artificial intelligent systems for medical text mining and medical image data processing.
- Discovery of disease bio-markers for diseases classification, early diagnosis and precision medication.
Haican Liu
Organization: National Institute for Communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention.
Current position: Deputy Director of Tuberculosis Laboratory / Associate Researcher

Education:
- 2003.09–2008.07 College of Public Health, Zhengzhou University, Henan, China (Bachelor's Degree of Medicine).
- 2008.9–2011.07 Chinese Center for Disease Control and Prevention, Beijing, China (Master Degree of Medicine).
- 2011.08–2014.07 Chinese Center for Disease Control and Prevention, Beijing, China (Doctor Degree of Medicine).

Professional experience:
2014.07– National Institute for Communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention.

Publications:

Research interests include:
M. tuberculosis genotyping, drug resistant, genomics and proteomics, and new TB vaccine.
Jinhua Liu
Organization: China Agricultural University, College of Veterinary Medicine, China Agricultural University
Current position: Professor

Dr. Liu received his DVM in 1985 and his PhD in 1997 from China Agricultural University (CAU) and had the post-doctoral training at Hokkaido University in Japan during 2000-2002. He is chair of department of preventive veterinary medicine, distinguished professor of CAU, recipient of National Science Foundation for Distinguished Young Scholars of China. He is a director of China Veterinary Poultry Association.

Publications:

Research interests include:
Dr. Liu interests include influenza at animal human interface, in particular the viral epidemiology, pathogenicity mechanism, and recombinant turkey herpesvirus-vector vaccine developments.
William J. Liu

Organization: National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention
Current position: Professor; Deputy Director of the Chinese National Influenza Center.

2000–2005 Bachelor Degree, Public Health Peking University, Health Science Center
2005–2010 PhD, Institute of Microbiology, Chinese Academy of Sciences
2010–2011 PostDoc. Institute of Biophysics, Chinese Academy of Sciences
2011–2012 PostDoc. Yale University, CT, US
2012–2013 Associate Professor, Institute of Microbiology, Chinese Academy of Sciences
2013–Present Professor, National Institute for Viral Disease Control and Prevention, China CDC

Awards:
2010 Excellent Young Professionals from Chinese Association of Immunology.
2017 The Top-notch Young Professionals from Organization Department, CCCPC
2017 The “Science and technology nova” from Beijing Science and Technology Commission
2017 The “Outstanding Alumni” from Alumni Association of Beijing Medical University
2018 Excellent Young Scholar from Natural Science Foundation of China

Publications:

Research interests include:
1. Prevention and control of influenza;
2. T-cell immunity to emerging and re-emerging viruses.
Yeming Wang
Organization: China-Japan Friendship Hospital
Current position: Physician of Department of Pulmonary and Critical Care Medicine
PhD degree at Capital Medical University, respiratory and critical medicine

Work Experience:
Sep, 2015-Jun, 2016
Sun yat-sen memorial hospital, sun yat-sen university,
Location: Guangzhou
Title: Resident
Duties: To treat patients, offering medical advices

Academic exchange:
• Aug–Sep, 2017 Welcome Trust Centre for Human Genetics, University of Oxford
• June–July, 2019 Welcome Trust Centre for Human Genetics, University of Oxford

Grants:
National Science and Technology Major Project (2017ZX10204401004), Emergency Special Project of the Ministry of Science and Technology (1060010000015001206)

Publications:
2. Yeming Wang, Guohui Fan, Peter Horby, Fredrick Hayden, Qian Li, Qiaoling Wu, Xiao-hui Zou, Hui Li, Qingyuan Zhan, Chen Wang, Bin Cao* for the CAP-China Network. Comparative outcomes of adults hospitalized with seasonal influenza A or B virus infection: application of the seven-category ordinal scale. Open Forum Infectious Diseases, https://doi.org/10.1093/ofid/ofz053
Zunyou Wu

Organization: National Center for AIDS/STD Control and Prevention, China CDC
Current position: Chief Epidemiologist
China CDC Director, Division of HIV Prevention, NCAIDS/China CDC

Education:
- PhD, Epidemiology, UCLA School of Public Health (1995)
- MPH, Public Health, UCLA School of Public Health (1992)
- MS, Epidemiology, Anhui Medical University (1988)
- MD, Medicine, Anhui Medical University (1985)

Grants and Awards:
- Grant number 2018ZX10721102, Grant title “Precision targeted intervention studies among high risk groups for HIV prevention in China”
- The Chinese Preventive Medicine Science and Technology Award, 2nd Class Award, Chinese Preventive Medicine Association, 2015
- The China National Award for Outstanding Contribution in Epidemiology, Chinese Preventive Medicine Association, 2014
- The Chinese Medical Science and Technology Award, 1st Class Award, Chinese Medical Association, Beijing, China, 2008
- The UNAIDS Gold Medal, 2008
- UCLA School of Public Health’s Alumni Hall of Fame, 2006
- International Rolleston Award, 2005

Professional experience:
His research findings have also been published in over 450 academic papers, and 252 of them have been in international scientific journals, including Science, Lancet. He also wrote 32 chapters including for Oxford Textbook for Public Health. Dr. Wu is active in promoting more supportive policies and environments for controlling HIV/AIDS in China. He is a leader in the field of HIV prevention strategies.

Publications:
Zifeng Yang
Organization: Guangzhou Institute of Respiratory Health
Current position: Professor

Education:

Awards:
The First Prize of Guangdong Province Science and Technology Progress (2019)

Professional experience:
- November. 2011– present Professor Guangzhou Institute of Respiratory Health (SKLRD) The First Affiliated Hospital of Guangzhou Medical University
- July. 2006- October. 2011 Assistant researcher. Guangzhou Institute of Respiratory Disease (SKLRD) The First affiliated Hospital of Guangzhou Medical College
- July. 2001- June. 2006 Internship, Assistant researcher. Institute of Tropical Medicine, Guangzhou University of Traditional Chinese Medicine.

Publications:
2. Yang ZF; Leung ELH; Liu L; Jiang ZH; Zhong NS. Developing influenza treatments using traditional Chinese medicine , Science, 2015, 347:S35~S37
3. Mok, CKP; Guan WD; Liu XQ; Lamers MM; Li XB; Wang M; Zhang TJS; Zhang QL; Li ZT; Huang JC; Lin JY; Zhang YH; Zhao P; Lee, HHY; Chen L; Li YM; Peiris JSM; Chen RC; Zhong NS; Yang ZF. Genetic Characterization of Highly Pathogenic Avian Influenza A(H5N6) Virus, Guangdong, China , Emerg. Infect. Dis., 2015, 21(12): 2268~2271.
Hui Zhang
Organization: National Center for TB Control, China CDC
Current position: Assistant Director

- 2006.7–present, Research Fellow, Assistant Director of National center for TB Prevention and Control, China CDC.
- 2000.9–2003.6, Master of Child and Adolescent Health, School of Public Health, Harbin Medical University.
- 1997.7–2000.7, Assistant, Department of Preventive Medicine, Baotou Medical College.
- 1992.9–1997.6, Bachelor of Medicine, Department of Preventive Medicine, Baotou Medical College.

Publications:
2. Added value of comprehensive program to provide universal access to care for sputum smear-negative drug-resistant tuberculosis, China. EID. 2019. (Correspondent author)

Research interests include:
Tuberculosis control strategy and measures; Tuberculosis epidemiology and risk factors; Tuberculosis Surveillance.
Linqi Zhang
Organization: Tsinghua University
Current position: Professor and Director Comprehensive AIDS Research Center
Tsinghua University, Beijing, China.

Professor Zhang has devoted 30 years to studying HIV-1 pathogenesis and vaccine development, and recently expanded his research into emerging and re-emerging human viral pathogens such as highly pathogenic avian influenza virus (HPAI), Middle East respiratory syndrome coronavirus (MERS-CoV), Ebola and Zika virus. Using cutting-edge antibody and combinatorial antigen library techniques, Professor Zhang’s team aims to characterize protective antibody immunity in infected humans and rationally design of effective vaccines and therapeutics against the viral infection. Professor Zhang is the Director of Comprehensive AIDS Research Center and Global Health and Infectious Diseases Research Center at Tsinghua University. He is a graduate of University of Edinburgh and holds associate professorship at the Aaron Diamond AIDS Research Center of Rockefeller University in New York before joining Tsinghua University in 2007. Professor Zhang is the recipient of National Outstanding Young Scientist Award and privileged Changjiang Professorship. He has published extensively and ranked No. 1 among the most cited Chinese Researchers in the field of microbiology and immunology surveyed by Elsevier in 2014, 2015 and 2016. Professor Zhang has also been serving as the member of national expert and advisory board to the Chinese government and several international organizations on HIV/AIDS and infectious diseases and recently been elected to the foreign fellow of African Academy of Sciences.

Publications:

Research interests include:
HIV-1 pathogenesis and vaccine development, and emerging human viral pathogens such as Middle East respiratory syndrome coronavirus (MERS-CoV), Ebola and Zika virus.
Yanlin Zhao

Organization: Chinese center for disease control and prevention
Current position: The director of National Tuberculosis Reference Laboratory of China CDC, and vice director of National Tuberculosis Control and Prevention Center, China CDC.

Dr. Zhao Yan-Lin, Ph.D & MD, a full professor of Chinese Centers for Disease Control and Prevention P. R. China. He is appointed as visiting professor of medical health school of Harvard medical university. He is the Chairperson of research branch of the Chinese Anti-TB Association from 2009 to now, and the head of TB research branch of Chinese Medical Association since 2010. Dr. Zhao is responsible for technical management of Chinese tuberculosis laboratory network capacity building-up and nationwide anti-TB drug resistance surveillance. He has published more than one hundred publications in international journals, such as NEJM, LANCET and so on.

Publications:


Research interests include:
Molecular epidemiology, epigenetics of tuberculosis mycobacterium, Drug resistance surveillance, New diagnostics.
Wenfei Zhu
Organization: National Institute for Viral Disease Control and Prevention, China CDC

- Aug 2018 – Present, National Institute for Viral Disease Control and Prevention, China CDC, Beijing, China. associate professor.
- Aug 2015 – Jul 2018, National Institute for Viral Disease Control and Prevention, China CDC, Beijing, China. research associate.
- Sep 2012 – Jul 2015, Chinese Center for Disease Control and Prevention, Beijing, China. Ph.D Student.

Publications:

Research interests include:
Dr. Wenfei Zhu works in the Chinese National Influenza Center, National Institute for Viral Disease Control and Prevention, China CDC. Her research interests include evolutionary analysis and pathogenicity mechanism study of zoonotic influenza viruses.
Mr. Artem Fadeev studied biophysics in Saint Petersburg Polytechnic University. Since 2012 he has been working in Laboratory of Molecular virology of Smorodintsev Research Institute of Influenza.

Publications:


Research interests include:

Mr. Artem Fadeev is a virologist whose research focuses on genetics of Influenza and other respiratory viruses.
Dina Glazkova
Organization: Center for Strategic Planning and Management of Biomedical Health Risks of the Ministry of Health of the Russian Federation
Current position: Senior researcher

Doctor of Philosophy in Molecular Biology, Department of Molecular Genetics of Yeast, Institute of Molecular Genetics, Russian Academy of Sciences

High education: Moscow Institute of Physics and Technology, Department of Physical and Chemical Biology, Moscow, Russia

- 2008 – Present – Research project – Gene therapy drug development for treatment of HIV infection
- 2003–2005 – Research project – Regulation of genes within the catecholamnergic system

Publications:


Research interests include:

Human immunodeficiency virus, retroviruses, gene therapy, viral vectors, vaccines.
Eduard Karamov

Current position: Head, Laboratory of Immunochemistry of the Gamaleya National Research Center of Epidemiology and Microbiology of the Russian Ministry of Health Principal Researcher, National Medical Research Center of Phthisiopulmonology and Infectious Diseases of the Russian Ministry of Health.

Eduard Karamov, PhD., DrSc, is involved in retrovirology research since 1985. The first Russian HIV strain was isolated in his laboratory. He supervised the development of first diagnostic tests for HIV, which were widely used in USSR and Russia, and antivirals used for AIDS treatment. He published over 150 articles in scientific journals and made over 200 presentations at international conferences and symposia. Professor Karamov authored four monographs and a textbook on virology. He was a supervisor in sixteen Ph.D. and Dr.Sci. fellowships. His lab served as a probation site for many scientists of the former USSR and Eastern Europe. He was a WHO expert (1988 – 2016), a member of the Vaccine Advisory Committee (VAC) of WHO, and a member of the editorial boards of AIDS and Lancet HIV. He is a UNAIDS scientific expert panellist, an academic editor of Medicine, and a member of editorial boards of several Russian peer-reviewed journals.


Publications:

Anastasiia Kholodnaia

Organization: FSBEI HE I.P. Pavlov SPbSMU MOH Russ
Current position: Assistant Professor, Department of Infectious Diseases and Epidemiology

- 2012 – graduated from First Pavlov State Medical University, Russia – Medical Doctor.
- 2013–2015 – specialization in infectious diseases – Department of Infectious Diseases and Epidemiology First Pavlov State Medical University, Russia.
- 2015–2018 – PhD course, research theme “Clinical and Pathogenetic Aspects of Illicit Opioid Exposure on Bacterial Translocation in HIV-infected People”, supervisor prof. D.A. Lioznov, Department of Infectious Diseases and Epidemiology First Pavlov State Medical University, Russia.
- Since 2017 – Assistant Professor, Department of Infectious Diseases and Epidemiology, First Pavlov State Medical University, Russia; co-investigator in RFBR-NIH project “St. PETER HIV – Alcohol, Protein Biomarkers and Cardiovascular Disease Risk”.

Publications:


Research interests include:
HIV-infection, immune system, microbiome, addictions
Andrei Kozlov

Current position: Director of the Biomedical Center, Chief, Lab of Molecular Virology, State Research Institute of Ultrapure Biologicals; Chief, Lab of Molecular Virology and Oncology, Peter the Great St. Petersburg Polytechnic University, leading scientist in Institute of General Genetics, Moscow.

In 1972 he graduated with honors from St. Petersburg State University (Department of Biochemistry). During the period 1972-1975, he completed postgraduate studies at the N.N. Petrov Research Institute of Oncology and successfully defended his Ph.D.

- 1978–1979 Fellowship of the International Agency for Research on Cancer (IARC)
- 1994–1995 Member of advisory group to Russian parliament (The State Duma) on HIV legislation
- 1998–2002 Coordinator, Russian HIV Vaccine Project
- 1998–2002 Member, Advisory Board for the Committee of Science & Education of the Russian Parliament (The State Duma)
- 1999 Russian National Chumakov Award for research in the field of immunobiotechnology.
- 2002 International Paul Harris Fellowship for contribution in fighting AIDS and other infectious diseases
- 2005 Vernadsky Award (from International Academical Union)
- 2005 Mechnikov Medal for research in the field of HIV vaccine
- 2006 Member, US Institute of Medicine (IOM) Committee on the Prevention of HIV Infection among Injecting Drug Users in High Risk Countries
- 2010– Member, Coordinating Board and Scientific Council, St. Petersburg Union of Scientists
- 2012– Expert, Scientific Research Institute – Federal Research Centre for Projects Evaluation and Consulting Services
- 2017– Expert, Russian Science Foundation

Publications:


Prof. Krasilnikov was educated at the Leningrad Polytechnic Institute, Physic-Mechanical Faculty of the specialty biophysics in 1975, defended his Ph.D. thesis (in Virology) in 1980 and the thesis of Doctor of Science (in Biotechnology) in 1999. He is an author of more than 130 publications and 27 patents, mainly in the fields of virology and production of biological substances such as vaccines and other immune biological medications including those blood-derived, bacteriophages, recombinant proteins.

In 1984 he had received an award from the Council of Ministers of the Soviet Union for the development and implementation of the vaccine against the tick-borne encephalitis. In 2018 he was the recipient of an International Eurasian award for development of corpuscular vaccines.

From 2003 to the end 2004, Prof. Krasilnikov served in Russia as a Manager General of UNDP (United Nations Development Program) project named “Development of the effective immunogenic vaccines and monitoring of their application”.

He is a Vice-President, Member of the Board of Russian Biotechnology Society named after academician Y. Ovchinnikov. Since 2003 to present time he serves as an international advisor to WHO in the field of vaccine development (the IVR program).

Research program of Prof. I. Krasilnikov focuses on:

1. basic technology of vaccines;
2. new adjuvants and their properties;
3. immunology of infectious processes.
Irina Leneva

Organization: Mechnikov Research Institute of Vaccines and Sera
Current position: Head of Laboratory

A broadly trained Ph.D. and Doctor of Science Virologist with extensive antiviral research and
development experience. Collaboration experience with start-up through big-size biotech- and
pharmaceutical companies. Proven track records in pharmaceutical research and development
from antiviral drug discovery program initiation through IND, Phase 3 and 4 clinical research.
Experience in both drug and vaccines areas. Hands-on experience with strategic planning, and
research alliance management.

Education:
- Postdoctoral studies in the laboratory of Genetic of RNA-Containing Viruses (Moscow In-
stitute for Viral Preparations, Ministry of Health of USSR.
- Wellcome Trust Fellow. Virology Lab, National Institute for Medical Research, Mill Hill,
  London.
- Visiting Scientist. Department of Virology, St. Jude Children’s Research Hospital. Memphis
  TN USA.

Professional experience:
- 01/2010 – present. I.Mechnikov Research Institute for Vaccines and Sera, Russian Acade-
  my of Science, Moscow, Russia. Head of Experimental Virology Laboratory.
- 02/1990–09/2007 Centre of Drug Chemistry, Moscow, Russia. Head of Virology Labora-
  tory, Department of Chemotherapy of Infectious.

Publications:
   Umifenovir susceptibility monitoring and characterization of influenza viruses isolated
   597.
   neva I.A., Shestakova I. V., Maleev V. V.Phamacoepidemiological study of the course of
   influenza and other acute respiratory viral infections in risk groups // Terapevticheskii
   of influenza virus: implications for the mechanism of anti-influenza action of arbidol. //
Dr. Vasiliy Leonenko studied applied mathematics in Omsk State University, Russia, and received his PhD in 2012 in the same university. Since 2014, he works in ITMO University, Saint Petersburg, Russia. Having influenza dynamics modeling as his primary area of research since 2015, he has published 11 articles in peer-reviewed journals on this topic and presented his results in several major conferences in computer science, modeling and epidemiology, namely, International Conference on Computational Science (ICCS 2015), Erice MathCompEpi2015, Epidemics6 (2017) and ESCAIDE 2018. In 2017, Dr. Leonenko was awarded a Fulbright Visiting Scholar grant for his project “Urban factors and the dynamics of communicable diseases: the use of reportable influenza data”, and he conducted a joint research on that topic at Center for Data Science, RTI International, Durham, USA (January-June 2018). In August of 2019, Dr. Leonenko participated in the collaborative research on the topic “Rank dynamics of influenza epidemics” funded by UNAM, Mexico.

Publications:


Research interests include:
Mathematical epidemiology, complex systems science, data science, high-performance computing.
Valentin Makarov
Organization: FSBI “Center of Strategic Planning and Management of Medical and Biological Risks”

Education:
• 2002-2007, Moscow State University, Biological faculty, Department of Virology – Master of biology;
• 2007-2010, Moscow State University, Biological faculty, Department of Virology – PhD in biology;

Grants and Awards:
• Grant RFFR № 15-34-50986 “Molecular mechanisms of the insecticidal action of short ssDNA fragments of the antiapoptotic gene of the baculovirus”
• Russian Federation President Grant MK-2072.2014.4 “Plant viruses: from structure studies to creating new nanomaterials”
• Grant RFFR № 15-54-04004 “The study of virus diversity and virus-like genetic elements in conifers: the search of the latent infection mechanisms”

Professional experience:
• 2010-2012, Moscow State University, Biological faculty, Department of Virology, Postdoctoral position
• 2012-2017, Moscow State University, A.N.Belosersky Institute of physico-chemical biology, Senior scientist.
• 2017-2019, FSBI “Center of Strategic Planning and Management of Medical and Biological Risks”, Deputy Head of the Department of Planning and Management of Medical and Biological Risks.

Publications:

Research interests include:
Microbiology, human microbiota, genome editing, gene-modified organisms.
Speakers

Aleksei Matveichev
Organization: NPO Petrovax Pharm, LLC
Current position: Head of Preclinical research center
PhD in Clinical Immunology, Allergology.

Russian Fund of fundamental research grants participant, 2009-2017:
- 07.2019 – till now – Head of Preclinical research center, NPO Petrovax Pharm, LLC
- 08.2017 – 07.2019 – Head of immunology group, Preclinical research center, NPO Petrovax Pharm, LLC

Publications:

Research interests include:
Cell immunology, dendritic cells, preclinical research, immune response, flow cytometry
Alexander Shestopalov
Organisation: Federal Research Center for Fundamental and Translational Medicine Siberian Branch of the Russian Academy of Sciences
Current position: Head of Division

Professional experience:

• 2019 – now – Head of Division Federal Research Center for Fundamental and Translational Medicine Siberian Branch of the Russian Academy of Sciences
• 2016–2019 – Actual Director Research Institute for Experimental and Clinical Medicine, Siberian Branch of the Russian Academy of Medical Sciences the Federal Agency of scientific organizations
• 2013–2016 – Head of Laboratory Research Centre for Clinical and Experimental Medicine, Siberian Branch of the Russian Academy of Medical Sciences, senior researcher at Novosibirsk State University
• 1991–2013 – Director, Division of Influenza and Zoonotic Infections, Federal State Research Center of Virology and Biotechnology "Vector", Koltsovo, Novosibirsk region, 630559 Russia and Senior researcher Novosibirsk state university.

Education:

• M.S. 1979 Novosibirsk State University, Department of Natural Sciences
• Ph.D.:1983 Siberian Computer Center, Novosibirsk
• Awards: Diploma of the Minister of Health of Russia, Award Society for the Study Infectious Diseases (International Society for Infectious Diseases)

Publications:


Research interests include:

Virology, zoonotic infections, ecology viruses infectious diseases of humans and animals.
German Shipulin
Organization: Federal State Budgetary Institution «Center for Strategic Planning and Management of Medical and Biological Health Risks» (Center for Strategic Planning, Russian Ministry of Health)
Current position: Deputy Director on Science and Production

In 1991 German Shipulin graduated from the Russian State Medical University named after N.I. Pirogov, Moscow (Department of Biochemistry, Medical-Biological faculty). In 2008 German Shipulin received his PhD degree in Epidemiology.

From 1992 up to 2018 German Shipulin had worked at the Central Research Institute for Epidemiology. He was the Head of Molecular diagnostics and epidemiology department, comprising over 1300 employees.

New diagnostic technologies based on amplification method (PCR in different formats, NASBA etc.) and sequencing method including NGS were developed and successfully implemented by German Shipulin’s employees.

Manufacture of highly sensitive PCR diagnostic kits for qualitative and quantitative detection and genotyping of infectious and parasitic agents by “MultiPrime” and “Real-Time PCR” methods was organized; new diagnostic kits on the basis of innovative pyrosequencing technology (AmpliSens Pyroscreen series) were developed.

Since 2009 within the scope of the federal program “National system of chemical and biological safety” German Shipulin’s department had developed a number of “Real-Time PCR” based diagnostic kits for multiplex molecular diagnosis of various special danger infections as well as test systems in planar oligonucleotide and protein biochips format.

Currently he is working as a Deputy Director on Science and Production in the Center for Strategic Planning, Russian Ministry of Health. He is managing, supervising and providing guidance to medical molecular diagnostics laboratories.

The number of scientific publications of German Shipulin exceeds 750 and he is a holder of more than 15 patents.

Research interests include:
Epidemiology and clinical course, diagnosis and prevention of new and newly emerging infections; current tendencies in epidemic process; molecular diagnostics; microbial ecology of the human body; clinical immunology, improvement of existing and development of new methods for diagnosis of infectious diseases.
Anna A. Shtro
Organization: Smorodinseyev Research Institute of Influenza
Current position: Head, laboratory of chemotherapy for viral infections

Education:

- M.Sc.: December, 2008 (Characterization of circulating influenza virus strains in terms of their resistance to rimantadine, Department of Genetics, St.Petersburg State University, Russia.)
- PhD: December, 2014 (Investigation of usnic acid derivatives activity against influenza virus)

Grants and Awards:

- 2015–2017. RSCF project “Cellular miRNAs as a novel molecular target for the acute viral infections therapy”
- 2017–2019. RFBR project “Development of new heterocyclic compounds as inhibitors of influenza neuraminidase”

Publications:


Research interests include:
Antivirals, Influenza, Virology, Respiratory viruses, Chemotherapy, Novel compounds
Mikhail Sinitsyn
Organization: Moscow Scientific and Clinical Center for TB Control
Current position: Acting Director, Organizer of public health, TB doctor, Thoracic surgeon, MD, Ph.D.

Education:
- 1999–2001 Sechenov Moscow Medical Academy, Department of Phthisiopulmonology (resident). Specialization: thoracic surgeon
- 1998–1999 Sechenov Moscow Medical Academy, Department of Phthisiopulmonology (resident). Specialization: TB-doctor
- Refresher courses: 2019 WHO “Implementing the WHO End TB strategy and new vision of TB elimination”
- 2017 Sechenov Moscow Medical Academy, Specialty: HIV-infection
- 2008 Sechenov Moscow Medical Academy, Specialty: Health Organization and Public Health
- Employment Record: 2018-to date Acting Director
- 2017–2018 Deputy Director for Scientific and Organizational
- 2014–2017 Moscow Scientific and Clinical Center for TB Control worked as Chief Medical Officer (for working with patients with HIV/TB co-infection)
- 2009–2014 Moscow Tubercular Clinical Hospital №3 worked as Deputy Chief Medical Officer and Head of the department of surgery.
- 2001–2009 Research Institute of Phthisiopulmonology Sechenov Moscow Medical Academy, worked as a thoracic surgeon, phthisiatrician doctor, since 2007 the Head of the department of surgery.

Field of professional activity: Organization of Health; diagnostic and differential diagnostic of tuberculosis and other lung diseases; thoracic surgery; diagnostic and treatment of tuberculosis, organization of prevention, detection, diagnosis and treatment of tuberculosis in patients with HIV infection.

Over 120 published works, including:

Research interests include:
Anna Sominina, Doctor of Medical Sciences degree, Honored Scientist of the Russian Federation, more than 100 publications in peer reviewed journals concerning enhancement of influenza and ORI surveillance, development of new MAb and diagnostic tests as well as long-term management of the NIC activity.

Project Management Experience:

- 2016–2019, CDC NU51IP000854 “Maintenance of Influenza Surveillance Capacity in Russia”, Principal Investigator.

Publications:


Research interests include:

Influenza vaccine effectiveness, hospital surveillance for SARI, genetic determinants of virus pathogenicity.
Oksana Stanevich
Organization: Smorodintsev Research Institute of Influenza
Current position: PhD Student

Education:
- First State Pavlov University, Saint-Petersburg, general medicine (2009 – 2015), medical doctor degree
- First State Pavlov University, Saint-Petersburg, internship at Infectious Diseases Department (2015–2016), physician, infectious diseases specialist degree
- Smorodintsev Research Institute of Influenza (Sept. 2018– up to present), PhD student

Additional education:
Bioinformatics Institute, educational program “Bioinformatics for biologists” (Sept. 2016 –Sept. 2017)

Grants:
Grant 14298GU/2019 from Foundation for Assistance to Small Innovative Enterprises (FASIE)

Publications:

Research interests include:
Infectious diseases, immunology, bioinformatics
Marina A. Stukova
Organization: Smorodintsev Research Institute of Influenza
Current position: Head of the Laboratory of Vectored Vaccine

Education:
- MD: Pavlov First Saint Petersburg State Medical University, Saint Petersburg, 1988
- PhD: Research Institute of Influenza, Saint Petersburg

2007 Grants and Awards:
Honorary diploma of the Ministry of Health of Russia for merits in the field of healthcare and many years of conscientious work dated 02.28.2019

Professional experience:
Coordinator and Investigator of more than 30 clinical trials of influenza vaccines (Phases I - III). Pre-clinical and clinical trials of influenza vectored vaccines against tuberculosis, RSV infection, universal Flu vaccine

Publications:

Research interests include:
Virology (influenza virus, RSV), molecular biology, vaccines (influenza virus based vector vaccines), immunology (virus-host interactions, post vaccination immunity), pre-clinical and clinical studies
Dr. Yuri Vasiliev has received PhD in virology from the Research Institute of Vaccines and Sera in Moscow in 2010, and since then has been working in the field of vaccinology with a focus on influenza. Most recent projects include next-generation influenza vaccines, alternative potency assays, as well as strategic frameworks on influenza control.

Dr. Yuri Vasiliev serves in various international workgroups and taskforces including WHO, GAVI, PATH and IFPMA.

He now works as an adviser for the St. Petersburg Research Institute of Vaccines and Sera (an IFPMA and DCVMN member), as well as an acting director of the Research Institute of Ultrapure Biologicals.

He has more than 100 published papers including those indexed in the WoS CC.

Publications:


Research interests include:
Influenza vaccines, effectiveness, immunogenicity, potency, correlates for protection, eradication.
Andrey Vasin

Organization: Smorodintsev Research Institute of Influenza
Current position: Head of WHO National Influenza Centre of Russia, Head of the Molecular Biology of Viruses Department

Organization: Peter the Great St. Petersburg Polytechnic University, Institute of Biomedical Systems and Biotechnologies
Current position: Professor, acting Director

In 2003 Andrey Vasin graduated from the Peter the Great St. Petersburg Polytechnic University (Department of Biophysics), MSc. 2005 – PhD (biochemistry), 2019 – D.Sc (biochemistry).

2019– to present – Professor, acting Director of the Institute of Biomedical Systems and Biotechnologies in Peter the Great St.Petersburg Polytechnic University;

2016– to present – Head of the Department of Molecular Biology of Viruses in Smorodintsev Research Institute of Influenza under the Ministry of Health of the Russian Federation;

2016–2019 – Director, Smorodintsev Research Institute of Influenza;

Scientific and administrative activities:

Head of the WHO National Influenza Center; member of WHO Working Group on Influenza Preparedness and Response, Director of the Global Virus Network Center in St-Petersburg, member of the Russian Society of Biochemists

Dr. Vasin is the author of more than 60 published works and PI and/or manager of more than 15 research projects and pre-clinical trials

Publications:


Research interests include:

Molecular virology, vaccinology, antiviral drugs development, molecular diagnostic, molecular biology and biotechnology.
Speakers

Vasiliy V. Vlassov

Organization: Center for Health Policy, National Research University Higher School of Economics, Moscow

Current position: Distinguished professor.

Education:
Military Medical Academy, SPb, Russia (Main field Epidemiology)
2010 Doctor of Sciences in Internal Diseases

Awards and Accomplishments:
- Member, Steering group, Evidence-informed Policy Network (EVIPNet, WHO Europe) 2007–2017
- Expert for Russian Academy of Science
- Civic Council at the Ministry of Health, Russian Federation
- Society for Evidence Based Medicine (osdm.org), president
- International Epidemiological Association

Professional experience:
- 2014 – Leading Scientist, Center for Health Policy, Higher School of Economics, Moscow, Russia
- 1998–2007 Director, Russian Branch, The Nordic Cochrane Centre
- Editorial Board Member: Clinical Epidemiology, European Journal of Public Health,

Publications:
Viacheslav Zhuravlev
Organization: St. Petersburg Federal Research Institute of Phthisiopulmonology, Russia.
Current position: MD., PhD. Associate Professor Head of the Laboratory Research Department

Degrees:
- 1999, PhD in phthisiology, FSBI “Saint-Petersburg Research Institute of Phthisiopulmonology” of the MoH of the RF,
- 1988, MD. Perm State Medical Institute, Faculty of Hygiene, Sanitation and Epidemiology.

Projects national:
- Project supported by Russian Foundation for Basic Research project 19-04-00263 Pathogenomic features and epidemic potential of highly resistant strains of ancient sublineage of Mycobacterium tuberculosis Beijing genotype 2019–2020
- Project supported by Russian Science Foundation 19-15-00028 Development of new efficient compounds against drug resistant Mycobacterium tuberculosis taking into account the population structure of the pathogen. 2019-2021
- Project supported by Russian Science Foundation 14-14-00292 Evolution of pathogenetic potential of phylogenetic lineages of Mycobacterium tuberculosis. 2014–2015

Publications:

Research interests include:
Certified specialist in pulmonology, phthisiology, clinical laboratory diagnostics and laboratory genetics. Scientific interest includes the study of clinical and laboratory manifestations of pulmonary tuberculosis and extra pulmonary tuberculosis in the context of HIV infection and diagnosis of MDR/XDR of mycobacterium tuberculosis.
EFFECTIVE MEASURE FOR PROTECTION AGAINST INFLUENZA AND ITS COMPLICATIONS IS VACCINATION

State Registration LP-005594 of June 19, 2019

QUADRIVALENT SPLIT-VIRION INACTIVATED INFLUENZA VACCINE

Production
Russian full-cycle production according to GMP standards
The active substances - influenza virus antigens - are obtained from purified type A and B influenza viruses grown separately in developing chicken embryos

Structure
The first Russian quadrivalent vaccine for the prevention of seasonal influenza, which meets all the WHO recommendations on the composition and amount of hemagglutinin of an influenza virus strain, contains 15 mcg of the influenza virus hemagglutinin of each strain (A/H1N1, A/H3N2, B line Yamagata, B line Victoria), just one dose of the vaccine contains 60 mcg
The vaccine does not contain preservatives, stabilizers and adjuvants

Result
Meets the immunogenicity criteria for inactivated influenza vaccines adopted in the European Union and the Russian Federation

Application
A single dose of Ultrix® Quadri vaccine forms a long-lasting immunity